Navigation Links
A New Strategy to Control Breast Cancer

A recent study finds that, TACE inhibitors currently developed for treating rheumatoid arthritis can also be employed to control proliferation of tumor cells. TACE is// strongly present in a form of breast cancer, which responds poorly to current therapies.

TACE (tumor necrosis factor-alpha-converting enzyme) acts like a “molecular scissors” that releases a pair of ligands, called Amphiregulin and TGF-alpha, from the cell surface. These ligands activate EGFR.

EGFR, which stands for Epidermal Growth Factor Receptor, is the protein on the outer surface of a cell that is activated by EGF and related growth factors and signals for the cell to divide. Given that one of the hallmarks of cancer is cell division run amok, the reduction of high levels of EGFR activity has long been a primary target for anti-cancer drug development. So far, however, drugs aimed at directly inhibiting EGFR activity have met with only limited success in the cancer clinic, primarily in a small number of lung cancers.

Bissell and Kenny, researchers with the U.S. Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab) have demonstrated that by targeting TACE (also known as ADAM17) with either molecular inhibitors or short interfering RNAs (siRNAs) that silence the TACE gene, the shedding of Amphiregulin and TGF-alpha ligands could effectively be blocked.

This also resulted in the inhibition of EGFR signaling and the reversion of malignant characteristics in tumor cells. It is the first reported use of protease inhibitors to stop breast cancer cell proliferation and restore the normal breast tissue structure.

Tumor cells, says Bissell, exist in the same microenvironment as healthy cells and must therefore appropriate normal physiological processes to facilitate their growth and spread. This idea can open up potential new avenues and targets for diagnostic and therapeutic applications.

“Because of this, we turned our attention to the processes that regulate the production of the ligands which bind and activate EGFR,” Kenny said. “We reasoned that this binding and activation is essential for EGFR activation and that finding a way to block this interaction might prove to be an important additional approach to explore for inhibition of this pathway.”

“We have designed an entirely new way of targeting EGFR signaling in breast cancer,” said Kenny. “Almost all the work to date has involved the use of antibodies that stick to kinases or drugs that block kinase activities.”

“Women with those types of tumors would seem to be poorly served by existing treatments and may stand to benefit from therapies that are based on the inhibition of TACE activity,” said Kenny. “We would like to see some of the companies who have developed the new generation TACE inhibitors for treatment of rheumatoid arthritis also consider evaluating them in cancer patients.”

“TACE inhibition has the potential to be an effective means of stopping tumor growth for EGFR-dependent cancers outside the breast as well,” she added.

Source-Erekalert
SRM
'"/>




Related medicine news :

1. Novel Strategy To Combat Alzheimer’s Disease
2. "Defensive Pessimism" Before Exam Results Not a Good Strategy
3. WHO Devises New Global Strategy To Fight Tuberculosis
4. HER-2 Positive Breast Cancer Patients May Benefit With a Combo Drug Strategy
5. West Nile Virus Can Be Tackled By New Strategy
6. Australia Set To Implement A national Strategy Tackle Cannabis Abuse
7. Clement Urged to Plot a National Pharmaceutical Strategy
8. New Preventive Strategy to Fight Childhood Obesity
9. Rae unveils Health-care Strategy
10. A Promising New Vaccination Strategy for Late-Stage Melanoma
11. Effective Strategy Against Bird flu-Spainish Flu Vaccine Raises Hopes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... ... , ... Mercy College is expanding its Graduate Business Programs to the Bronx ... to high demand: Master of Business Administration (MBA), Master of Organizational Leadership (MSOL) and ... School of Business Graduate Program Chair Dr. Ray Manganelli said: “We believe that people ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Council for Graduate Medical Education (ACGME) that it has received accreditation for its ... accreditation of three residency programs that Memorial is currently pursuing, including Pediatrics and ...
(Date:4/29/2016)... Atlanta, Georgia (PRWEB) , ... April 29, 2016 , ... ... 60 rural hospitals across the Southeast, celebrated the signature of Gov. Nathan Deal on ... by Rep. Geoff Duncan (R - Cumming), offers a 70% tax credit to individuals ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House announced efforts ... more information about their loan terms and accounts, and more protections for borrowers. ... federal and private loans, has reached $1.3 trillion, with 43 million Americans holding ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... infants born with severe congenital diaphragmatic hernia have better survival rates if surgery ... diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... ORANGE COUNTY, Calif. , April 29, 2016 ... technology industry is projected to shift from systems ... can replace all types of modality CRT Medical ... set-up." Although there are a host of foreseeable ... a serious concern; will existing modalities have to ...
(Date:4/29/2016)... April 29, 2016 ReportsnReports.com ... 2016" market research report that provides an overview ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
(Date:4/29/2016)... April 29, 2016 Acquisition ... Sciences, Product Development Capabilities in North ... Base . Indegene ( http://www.indegene.com ... the acquisition of Skura Corporation,s life science business. ... adaptive sales enablement technology for life science organizations ...
Breaking Medicine Technology: